Litcius/Paper detail

Mesenchymal stem cell-derived extracellular vesicles for cell-free therapy of ocular diseases

Xiaoling Liu, Liang Hu, Fei Liu

2022Extracellular Vesicles and Circulating Nucleic Acids16 citationsDOIOpen Access PDF

Abstract

Mesenchymal stem cells-derived extracellular vesicles (MSC-EVs) have noticeably attracted clinicians' attention in treating ocular diseases. As the paracrine factor of MSCs and an alternative for cell-free therapies, MSC-EVs can be conveniently dropped over the ocular surface or diffused through the retina upon intravitreal injection, without increasing the risks of cellular rejection and tumor formation. For clinical translation, a standardized and scalable production, as well as reprogramming the MSC-EVs, are highly encouraged. This review aims to assess the potential approaches for EV production and functional modification, in addition to summarizing the worldwide clinical trials initiated for various physiological systems and the specific biochemical effects of MSC-EVs on the therapy of eye diseases. Recent advances in the therapy of ocular diseases based on MSC-EVs are reviewed, and the associated challenges and prospects are discussed as well.

Topics & Concepts

Mesenchymal stem cellParacrine signallingCell therapyMedicineExtracellular vesiclesReprogrammingStem-cell therapyClinical trialExtracellular vesicleCellStem cellMicrovesiclesCancer researchBioinformaticsPathologyBiologyCell biologyInternal medicineReceptorBiochemistryGenemicroRNAGeneticsExtracellular vesicles in diseaseRNA Interference and Gene DeliveryMicroRNA in disease regulation
Mesenchymal stem cell-derived extracellular vesicles for cell-free therapy of ocular diseases | Litcius